SA520412281B1 - Vegf تركيبة سائلة تشتمل على مضاد عامل النمو البطاني الوعائي - Google Patents

Vegf تركيبة سائلة تشتمل على مضاد عامل النمو البطاني الوعائي

Info

Publication number
SA520412281B1
SA520412281B1 SA520412281A SA520412281A SA520412281B1 SA 520412281 B1 SA520412281 B1 SA 520412281B1 SA 520412281 A SA520412281 A SA 520412281A SA 520412281 A SA520412281 A SA 520412281A SA 520412281 B1 SA520412281 B1 SA 520412281B1
Authority
SA
Saudi Arabia
Prior art keywords
composition
liquid composition
vegf antagonist
protein
stabilization
Prior art date
Application number
SA520412281A
Other languages
English (en)
Inventor
يونجكووك كيم
جايمين لي
،اناي كيم
وونجيونغ يوو
يونج مين جانج
يونجسيوك جونج
Original Assignee
سامسونج بيوبيس كو ، ليمتد.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66994837&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SA520412281(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by سامسونج بيوبيس كو ، ليمتد. filed Critical سامسونج بيوبيس كو ، ليمتد.
Publication of SA520412281B1 publication Critical patent/SA520412281B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

يتم توفير: تركيبة لتحقيق الثبات لبروتين، تشتمل التركيبة على محلول منظم يشتمل على فوسفات الصوديوم، أو الهيستيدين، أو توليفة منها، ومثبت لا يشتمل على كلوريد الصوديوم و/أو يشتمل على واحد على الأقل تم اختياره من المجموعة التي تتكون من تريهالوز، سكروز، ومانيتول؛ تركيبة سائلة مثبتة لبروتين، تحتوي على التركيبة لتحقيق الثبات وبروتين؛ وطريقة لتحضير تركيبة سائلة مثبتة باستخدام التركيبة لتحقيق الثبات.
SA520412281A 2017-12-22 2020-06-20 Vegf تركيبة سائلة تشتمل على مضاد عامل النمو البطاني الوعائي SA520412281B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20170178693 2017-12-22

Publications (1)

Publication Number Publication Date
SA520412281B1 true SA520412281B1 (ar) 2024-01-25

Family

ID=66994837

Family Applications (1)

Application Number Title Priority Date Filing Date
SA520412281A SA520412281B1 (ar) 2017-12-22 2020-06-20 Vegf تركيبة سائلة تشتمل على مضاد عامل النمو البطاني الوعائي

Country Status (11)

Country Link
US (1) US20200390693A1 (ar)
EP (1) EP3730126B1 (ar)
JP (2) JP7692699B2 (ar)
KR (3) KR102494021B1 (ar)
CN (1) CN111556744B (ar)
AU (1) AU2018388301B2 (ar)
CA (2) CA3085158C (ar)
IL (1) IL275238B2 (ar)
SA (1) SA520412281B1 (ar)
TW (1) TWI848956B (ar)
WO (1) WO2019124946A1 (ar)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
MX2020005170A (es) 2017-11-17 2020-10-16 Amgen Inc Formulaciones de proteinas de fusion vegfr-fc.
WO2019124946A1 (ko) 2017-12-22 2019-06-27 삼성바이오에피스 주식회사 Vegf 길항제를 포함하는 액상 조성물
DK4364724T3 (da) * 2018-05-10 2025-12-22 Regeneron Pharma Formuleringer med høj koncentration af VEGF-receptorfusionsprotein
AU2021268026A1 (en) 2020-05-08 2023-01-19 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer
CN116056688A (zh) * 2020-07-24 2023-05-02 盼展生物技术有限公司 眼用液体组合物
CA3190325A1 (en) * 2020-07-31 2022-02-03 Celltrion Inc. Stable pharmaceutical preparation
US11723955B1 (en) * 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition
TWI831202B (zh) * 2022-05-13 2024-02-01 新源生物科技股份有限公司 血管內皮生長因子受體融合蛋白醫藥組合物
TWI892441B (zh) * 2022-05-13 2025-08-01 新源生物科技股份有限公司 血管內皮生長因子受體融合蛋白醫藥組合物
WO2025177156A1 (en) * 2024-02-20 2025-08-28 Lupin Limited Stable ophthalmic pharmaceutical formulation of aflibercept

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101433715B (zh) 1999-06-08 2013-04-17 里珍纳龙药品有限公司 具有改善的药物动力学特性的修饰嵌合多肽
ES2633574T3 (es) 2005-03-25 2017-09-22 Regeneron Pharmaceuticals, Inc. Formulaciones de antagonistas de VEGF
US9283260B2 (en) * 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
AU2012202859C1 (en) * 2006-06-16 2025-08-07 Regeneron Pharmaceuticals, Inc. VEGF antagonist formulations suitable for intravitreal administration
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
CN103816115B (zh) * 2010-08-31 2017-06-27 成都康弘生物科技有限公司 一种含有抑制血管增生的融合蛋白的药物组合物及用途
UY34105A (es) * 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
BR112014009146A8 (pt) * 2011-10-18 2017-06-20 Coherus Biosciences Inc formulações de etanercepte estabilizadas com aminoácidos
AU2013267310A1 (en) 2012-06-01 2014-12-11 Ophthotech Corporation Compositions comprising an anti-PDGF aptamer and a VEGF antagonist
MX351261B (es) * 2012-06-01 2017-10-06 Surmodics Inc Aparato y método para recubrir catéteres con globo.
CN110538322A (zh) * 2013-03-13 2019-12-06 豪夫迈·罗氏有限公司 抗体配制剂
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
KR101808234B1 (ko) * 2015-06-23 2017-12-12 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
LT3386541T (lt) * 2015-12-07 2020-10-26 Merck Patent Gmbh Vandeninė farmacinė kompozicija, apimanti anti-pd-1 antikūną avelumabą
CA3010329A1 (en) * 2015-12-29 2017-07-06 Oncobiologics, Inc. Buffered formulations of bevacizumab
JP7116059B2 (ja) * 2016-11-21 2022-08-09 ジャスト－エヴォテック バイオロジックス、インコーポレイテッド アフリベルセプト製剤及びその使用
EP3684538B1 (de) * 2017-09-22 2025-02-26 SKS Welding Systems GmbH Schweissstromquelle mit einer kühleinrichtung
WO2019124946A1 (ko) 2017-12-22 2019-06-27 삼성바이오에피스 주식회사 Vegf 길항제를 포함하는 액상 조성물
DK4364724T3 (da) * 2018-05-10 2025-12-22 Regeneron Pharma Formuleringer med høj koncentration af VEGF-receptorfusionsprotein

Also Published As

Publication number Publication date
EP3730126A4 (en) 2021-11-03
EP3730126C0 (en) 2025-05-14
KR102494021B1 (ko) 2023-02-06
CA3189025A1 (en) 2019-06-27
JP7692699B2 (ja) 2025-06-16
CA3085158A1 (en) 2019-06-27
US20200390693A1 (en) 2020-12-17
KR20200084897A (ko) 2020-07-13
KR20230021164A (ko) 2023-02-13
KR20250002808A (ko) 2025-01-07
CN111556744A (zh) 2020-08-18
AU2018388301B2 (en) 2022-02-17
NZ765415A (en) 2024-08-30
EP3730126B1 (en) 2025-05-14
TW202023603A (zh) 2020-07-01
BR112020012399A2 (pt) 2020-11-24
IL275238B2 (en) 2023-12-01
JP2022166159A (ja) 2022-11-01
IL275238A (en) 2020-07-30
CA3085158C (en) 2023-04-04
IL275238B1 (en) 2023-08-01
CN111556744B (zh) 2023-12-29
WO2019124946A1 (ko) 2019-06-27
TWI848956B (zh) 2024-07-21
AU2018388301A1 (en) 2020-07-02
EP3730126A1 (en) 2020-10-28
JP2021508687A (ja) 2021-03-11
KR102742284B1 (ko) 2024-12-16

Similar Documents

Publication Publication Date Title
SA520412281B1 (ar) Vegf تركيبة سائلة تشتمل على مضاد عامل النمو البطاني الوعائي
JO3772B1 (ar) صيغة جسم مضاد لـ cgrp
MX2017016169A (es) Anticuerpos anti-her2 y metodos de uso.
EP4360652A3 (en) Adeno-associated virus formulations
MX2018001497A (es) Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
EP4385521A3 (en) Storage stable compositions and methods for the treatment of refractive errors of the eye
MX390903B (es) Composición y método para el crecimiento del cabello.
MX2018016038A (es) Compuestos y metodos para modular la funcion del acido ribonucleico (arn).
MX2018008190A (es) Sistemas y metodos para la administracion transdermica a largo plazo.
BR112017004393A2 (pt) formulações de anticorpo
GB2546432A (en) Apertured fibrous structures and methods for making same
MX2018004674A (es) Moduladores de interacción de sestrina-gator2 y sus usos.
MX2021006674A (es) Composiciones para estabilizar bacterias y usos de las mismas.
MX2018000395A (es) Proteinas y composiciones inmunizantes que contienen proteinas de klebsiella y metodos de uso.
PH12017502123A1 (en) Substituted benzamides and methods of use thereof
MX387269B (es) Formulaciones de factor ix liofilizadas.
SI3927614T1 (sl) Žiroskopski stabilizator
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
MX2021006102A (es) Suministro mejorado de agentes grandes.
PH12020551618A1 (en) Erenumab compositions and uses thereof
MX2019008338A (es) Composicion farmaceutica que contiene sulglicotido o una sal farmaceuticamente aceptable del mismo para la prevencion o tratamiento del ojo seco.
EP3607969A4 (en) INFLAXIMAB COMPOSITION WITH HISTIDINE BUFFER SYSTEM
MX2016015366A (es) Una composicion de toxicidad baja.
PH12020551582A1 (en) Lfa3 variants and compositions and uses thereof
EP3849307C0 (en) DOUBLE CHAMBER VIAL FOR CORNEAL GRAFT STORAGE